chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Vaccination site pain
Clinical narrative: Injection site arm pain; muscle aches; This is a spontaneous report received from a contactable consumer, the patient. A 30-year-old non pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER2613) via an unspecified route of administration in the left arm on 26Mar2021 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. No medical history of the patient was reported. The patient reported of no known allergies. The other medication received in two weeks was cetirizine hydrochloride (ZYRTEC) for unknown indication. The patient did not receive other vaccines within 4 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Post the vaccination the patient had not been tested for COVID-19 . On 26Mar2021, the patient experienced vaccination site arm pain and muscle aches. The patient did not receive any treatment for the event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events vaccination site arm pain and muscle aches was recovering at the time of report.   No follow-up attempts possible. No further information expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Chest discomfort, Ear pain, Fatigue, Lymphadenopathy
Clinical narrative: Swelling in glands/lymph nodes; earache (right ear); burning and tightness in chest; burning and tightness in chest; Aches; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 60- years-old non pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ep6955) via unspecified route of administration in the left arm on 15Mar2021 at 15:15 (at the age of 60-years old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient experienced swelling in n glands/lymph nodes, earache (right ear), burning and tightness in chest, aches and fatigue on 19Mar2021. The patient underwent lab tests and procedure which included COVID test (Nasal swab) on an unknown date and tested negative. The events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive treatment for the reported events. The clinical outcome of events swelling in n glands/lymph nodes, earache (right ear), burning and tightness in chest, aches and fatigue was not resolved. No follow-up attempts are needed. No further information expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, SARS-CoV-2 test
Clinical narrative: Swelling in glands/lymph nodes; earache (right ear); burning and tightness in chest; burning and tightness in chest; Aches; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 60- years-old non pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ep6955) via unspecified route of administration in the left arm on 15Mar2021 at 15:15 (at the age of 60-years old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient experienced swelling in n glands/lymph nodes, earache (right ear), burning and tightness in chest, aches and fatigue on 19Mar2021. The patient underwent lab tests and procedure which included COVID test (Nasal swab) on an unknown date and tested negative. The events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive treatment for the reported events. The clinical outcome of events swelling in n glands/lymph nodes, earache (right ear), burning and tightness in chest, aches and fatigue was not resolved. No follow-up attempts are needed. No further information expected.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Severe full body rash starting at neck and continuing to toes; This is a spontaneous report received from a contactable consumer, the patient. A 81-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 09Feb2021 (at the age of 81-years-old), as a single dose for COVID-19 immunisation and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205), via an unspecified route of administration on 02Mar2021 at 11:30 (at the age of 81-years-old), as a single dose for COVID-19 immunisation. Medical history included high blood pressure and high cholesterol. Concomitant medications were not reported. The patient had not diagnosed with COVID-19 prior to vaccination. Since the vaccination, the patient had not been tested for COVID-19. On an unspecified date in 2021, the patient experienced severe full body rash starting at neck and continued to toes. Therapeutic measures were taken as a result of severe rash and included treatment with prednisone. The adverse event did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome for the event severe rash was not resolved at the time of this report.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Ringing in both my ears, predominant in right ear; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER8727) via an unspecified route of administration in left arm on 21Mar2021 at 14:15 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included migraine. Concomitant medications included topiramate (MANUFACTURER UNKNOWN) 100mg twice daily and propranolol (MANUFACTURER UNKNOWN) 25mg twice daily for an unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6203) via an unspecified route of administration in left arm on 28Feb2021 at 16:15 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. The patient past drug history included codeine and was allergic to it. The patient was not diagnosed with COVID-19, prior to vaccination. The patient had not tested for COVID-19, since the vaccination. On 22Mar2021 at 12:00, the patient experienced ringing in both ears, right ear more prominent beginning day after second dose and continued with intensity each day after and it had been 6 days. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of ringing in ears was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 82.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Rash
Clinical narrative: Inappropriate schedule of vaccine administered; rash on both arms and legs; This is a spontaneous report from a contactable consumer, the patient. A 82-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 19Mar2021 at 10:00 hours (at the age of 82-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number:3758 ) via an unspecified route of administration in the left arm on 19Mar2021(at the age of 82-years-old) as a single dose for COVID-19 immunisation( inappropriate schedule of vaccine administered). The patient had no known allergies to medicines, food or other products. The patient did not receive any medications within two weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccine within four weeks prior to vaccination. On 25March2021 at 05:00 hours after 7 days of vaccination, the patient experienced rash on both arms and legs. No treatment was received for the adverse event. The clinical outcome of the event rash on both legs and arms were recovering at the time of this report.  No follow up attempts are possible; Information about lot/batch number cannot be obtained.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Pain, Pyrexia
Clinical narrative: Body aches; Felt feverish; Chills; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204), via an unspecified route of administration in the left arm on 24Mar2021 at 13:00 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. The patient was allergic to penicillin and sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN), estradiol (MANUFACTURER UNKNOWN), progesterone (MANUFACTURER UNKNOWN) and paroxetine hydrochloride (PAXIL), all for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER COVID-19 mRNA VACCINE BIONTECH; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 03Mar2021 at 13:00 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 25Mar2021 at 02:00, the patient felt feverish. The patient had chills, body aches and fatigue approximately 12-13 hours after second dose. Symptoms persisted for 48 hours. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events felt feverish, chills, body aches and fatigue. The clinical outcomes of the events felt feverish, chills, body aches and fatigue were recovering at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Hyperhidrosis, Nausea, Pain in extremity
Clinical narrative: Throwing up non Stop; intense nausea; headache; Soreness in arm.; fever; chills; Sweating; This is a spontaneous report received from a contactable consumer, the patient. A 31-year-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via unspecified route of administration in the left arm on 26Mar2021 at 15:00 (at the age 31-years-old), as a single dose for COVID-19 immunisation. The medical history and concomitant medications were not reported. Prior to vaccination, patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient previously received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date, as single dose for COVID-19 immunisation. On 27Mar2021, the patient experienced throwing up non-stop, intense nausea, headache, soreness in arm, fever, chills and sweating. The events resulted in doctor or other healthcare professional office and clinic visit. The patient had received treatment with ZOFRAN for the reported events. The clinical outcome of the event vomiting, nausea, headache, pain in arm, fever, chills and sweating was recovering.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vomiting
Clinical narrative: Throwing up non Stop; intense nausea; headache; Soreness in arm.; fever; chills; Sweating; This is a spontaneous report received from a contactable consumer, the patient. A 31-year-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via unspecified route of administration in the left arm on 26Mar2021 at 15:00 (at the age 31-years-old), as a single dose for COVID-19 immunisation. The medical history and concomitant medications were not reported. Prior to vaccination, patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient previously received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date, as single dose for COVID-19 immunisation. On 27Mar2021, the patient experienced throwing up non-stop, intense nausea, headache, soreness in arm, fever, chills and sweating. The events resulted in doctor or other healthcare professional office and clinic visit. The patient had received treatment with ZOFRAN for the reported events. The clinical outcome of the event vomiting, nausea, headache, pain in arm, fever, chills and sweating was recovering.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 23.0
Sex: M
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: severe vomitting; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old male patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 MRNA vaccine; Lot number: unknown), via an unspecified route of administration on 27Mar2021 at 10:30 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. Patient had no relevant medical history. The patient did not receive any other medications within two weeks. The patient had no known allergies to food, medications or other products. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 27Mar2021 at 12:15, the patient experienced severe vomiting. It was unknown if the patient received treatment for the event. The clinical outcome of severe vomiting was not resolved.   No follow-up attempts are possible; information about lot number cannot be obtained.
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Lethargy, Malaise, Myalgia
Clinical narrative: General lethargy; Random muscle/joint aches; Generally feeling unwell; Random muscle/joint aches; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old adult male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EP7533), via an unspecified route of administration in left arm on 26Mar2021 at 16:15 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. No medical history was reported. The patient had no known allergies. Concomitant medications included cetirizine hydrochloride (ZYRTEC) and bupropion hydrochloride (WELLBUTRIN) used for unknown indication from unspecified date. The patient also took unspecified vitamin once a day. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 27Mar2021 at 07:30, the patient experienced general lethargy, random muscle pain, joint aches and generally felt unwell. The patient did not receive any treatment for these events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of general lethargy, random muscle pain, joint aches and generally felt unwell was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Cough, Nasal congestion, Oropharyngeal pain
Clinical narrative: Cough; stuffy nose and congestion; sore throat; sinus pressure; loss of taste; loss of smell; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 24Mar2021 at 09:45 (at the age of 42-years-old), as a single dose for COVID-19 immunisation. The patient had no relevant past medical history. The patient had no allergies to medications, food, or other products. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 26Feb2021 at 17:00 (at the age of 42-years-old), as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 24Mar2021 at 13:00, the patient experienced cough, stuffy nose and congestion (nasal congestion), sore throat, sinus pressure, loss of taste, and loss of smell. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcomes of the events cough, stuffy nose and congestion, sore throat, sinus pressure, loss of taste and loss of smell were not recovered.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Paranasal sinus discomfort
Clinical narrative: Cough; stuffy nose and congestion; sore throat; sinus pressure; loss of taste; loss of smell; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 24Mar2021 at 09:45 (at the age of 42-years-old), as a single dose for COVID-19 immunisation. The patient had no relevant past medical history. The patient had no allergies to medications, food, or other products. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 26Feb2021 at 17:00 (at the age of 42-years-old), as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 24Mar2021 at 13:00, the patient experienced cough, stuffy nose and congestion (nasal congestion), sore throat, sinus pressure, loss of taste, and loss of smell. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcomes of the events cough, stuffy nose and congestion, sore throat, sinus pressure, loss of taste and loss of smell were not recovered.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Anosmia
Clinical narrative: lost my sense of smell and taste; lost my sense of smell and taste for 20 minutes; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955), via an unspecified route of administration in the left arm on 21Mar2021 at 15:30 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not have allergies to medications, food, or other products. The patient did not receive concomitant medications within 2 weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 21Mar2021 at 20:30, about 5 hours after the vaccination, the patient lost her smell and taste for 20 minutes ("luckily it didn't last"). The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events lost her smell and taste for 20 minutes. The clinical outcomes of the events lost her smell and taste for 20 minutes were recovered on 21Mar2021 at 20.50.  No follow-up attempts are needed. No further information is expected.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea
Clinical narrative: pt had difficulty breathing a few minutes after receiving her second dose of Pfizer Covid vaccine.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Decreased appetite, Nausea, Pain, Pyrexia
Clinical narrative: Severe body aches; fever of 102 all day the following day and continuing; Nausea; Loss of appetite; This is a spontaneous report from a non-contactable consumer, the patient. A 31-year-old non-pregnant female patient received a second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 23Mar2021 at 18:30 hrs (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19 Since the vaccination, the patient had not been tested positive for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within 2 weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 02Mar2021 at 18:30 hrs (at the age of 30-years-old) as a single dose for COVID-19 immunisation. On 24Mar2021 at 05:00 hrs, the patient experienced severe body aches, fever of 102 (unspecified unit) all day the following day continuing, loss of appetite and nausea. The events did not result in a doctor or other healthcare professional office/clinic visit, and the emergency room/department or urgent care The patient did not receive any treatment for the events. The clinical outcome for the events severe body aches, fever of 102, loss of appetite and nausea was not recovered at the time of the report.   Information about lot/batch number cannot be obtained. No further information expected.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Headache
Clinical narrative: Minor soreness in left shoulder (where vaccine was delivered); Very minor headache; This is a spontaneous report from a non-contactable consumer, the patient. A 45-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3247) via an unspecified route of administration in the left arm on 23Mar2021 at 12:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not have a history of allergies. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration as a single dose for COVID-19 immunisation on an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not been tested for COVID-19. On 23Mar2021 at 17:00, the patient experienced minor soreness in the left shoulder where vaccine was administered and a very minor headache. The patient did not receive any treatment for the reported events. Adverse event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events shoulder soreness and the headache was resolving at the time of this report.  No follow-up attempts are possible. No further information expected.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Feeling abnormal, Pruritus, Rash
Clinical narrative: Splotchy rash and bumps on stomach, feet, legs.; Very itchy feet and itching around body; Head feels a little foggy.; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: En6204), via an unspecified route of administration in the left arm on 24Mar2021 at 11:00 (at the age of 27-years-old), as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. The patient did not take any concomitant medications. The patient previously received azithromycin (ZITHROMAX) and amoxicillin (MANUFACTURER UNKNOWN); both on unknown dates for unspecified indications and experienced drug allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 24Mar2021 at 18:30, the patient experienced splotchy rash and bumps on stomach, feet, legs, very itchy feet and itching around body and head felt a little foggy. It was unknown if any therapeutic measures were taken as a result of the events. The clinical outcome of the events rash, itching and foggy feeling in head was unknown at this time of report.   No follow-up attempts are needed. No further information is expected.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Dry mouth, Glossodynia, Paraesthesia oral, Tongue disorder, Tongue movement disturbance
Clinical narrative: lips felt tingle; tongue dexterity affected; tongue became sensitive to eventoothpaste; tongue felt thickened; Very dry mouth; This is a spontaneous report from a contactable consumer, the patient. A 77-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6206), via an unspecified route of administration in the left arm on 04Mar2021 at 11:00 (at the age of 77-years-old), as a single dose for COVID-19 immunisation. Medical history included high blood pressure and cholesterol. Concomitant medication included amlodipine (MANFACTURER UNKNOWN) and simvastatin (MANFACTURER UNKNOWN); both for unknown indications from unknown dates. The patient did not have allergies to medications, food, or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 04Mar2021 at 17:00 (after 4+ hours receiving the first dose), the patient's lips felt tingle and her tongue dexterity affected and tongue became sensitive to even toothpaste, tongue felt "thickened" although no problem in swallowing. The patient also had very dry mouth. The patient took BENADRYL as a therapeutic measure, symptoms persisted but lessened, she was apprehensive about taking second dose. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events lips felt tingle, tongue dexterity affected, tongue became sensitive to even toothpaste, tongue felt thickened and dry mouth was resolving.  No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia, Salivary hypersecretion, Taste disorder
Clinical narrative: Strong metallic taste in mouth; Some taste altered; Watery mouth; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: En6201), via an unspecified route of administration in the left arm on 21Mar2021 at 15:45 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient was allergic to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included montelukast (MANUFACTURER UNKNOWN), fluticasone propionate; salmeterol xinafoate (ADVAIR), aspirin (MANUFACTURER UNKNOWN), vitamin (MANUFACTURER UNKNOWN) and doxycycline (MANUFACTURER UNKNOWN), all for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Em9810), via an unspecified route of administration in the left arm on 21Feb2021 at 15:00 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 22Mar2021 at 14:00, the patient experienced strong metallic taste in mouth, watery mouth and some taste altered. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events strong metallic taste in mouth, watery mouth and some taste altered. The clinical outcomes of the events strong metallic taste in mouth, watery mouth and some taste altered were not recovered at the time of the report.   No follow-up attempts are needed. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, SARS-CoV-2 test positive
Clinical narrative: Her husband was tested positive on Monday; This is a spontaneous report from a contactable consumer (patient's wife). This is the second case out of 2 cases.   A male patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection; Batch/Lot number, expiry date, NDC number and UPC number was reported as unknown) via an unspecified route of administration on 10Mar2021, as a single dose for covid-19 immunization. Medical history and concomitant medications were not reported. The patient was tested positive for covid-19 on 22Mar2021. The patient was scheduled to get the second dose on 31Mar2021. She wanted to know if they need to reschedule for the second dose. The patient underwent laboratory tests and procedures which included sars-cov-2 test as positive on 22Mar2021. The outcome of the event of tested positive for covid-19 was unknown.   Information on the lot/batch number had been requested.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling abnormal, Nausea, Pain, Vomiting
Clinical narrative: Brain fog; Burning pain in both arms and body; Vomiting; Nausea; This is a spontaneous report from a non-contactable consumer, the patient. A 30-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205), via an unspecified route of administration in the right arm on 03Mar2021 (at the age of 30-years-old) and the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730), via an unspecified route of administration in the left arm on 25Mar2021 (at the age of 30-years-old), as single doses for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medication included cetirizine hydrochloride (ZYRTEC) for an unknown indication from an unknown date. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On an unknown date in Mar2021, the patient experienced vomiting, nausea, brain fog and burning pain in both arms and body. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events vomiting, nausea, brain fog and burning pain in both arms and body. The clinical outcomes of the events vomiting, nausea, brain fog and burning pain in both arms and body were not recovered at the time of the report. No follow-up attempts are possible. No further information is expected.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Breast discomfort, Breast tenderness, Pruritus
Clinical narrative: breast tender; Right breast nipple very itchy; breast felt a bit full; This is a spontaneous report from a non-contactable consumer, the patient. A 70-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL9264) via an unspecified route of administration in the right arm on 06Feb2021 at 16:15 (at the age of 70-year-old) as a single dose for COVID-19 immunisation and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN 6202) via an unspecified route of administration in the right arm on an unknown date, as a single dose for COVID-19 immunisation. Medical history included menieres disease and the patient was allergic to iodine, sulfa antibiotics, shellfish, fish, mushrooms and animals. Concomitant medications included triamterene/hctz (hydrochlorothiazide) 37.5/25 (unit unspecified) (MANUFACTURER UNKNOWN), travoprost (TRAVATAN), timolol (BETIMOL) and levocabastine hydrochloride (ZYRTEC) for unknown indication from unknown date. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 10Feb2021 (3-4 days after vaccination), the patient experienced right breast nipple very itchy and then tender. The breast felt a bit full and slightly tender. It was reported that, the patients symptoms were improved, then felt of fullness and tenderness in right breast again after second dose. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. The clinical outcome of the events itchy, breast heaviness and breast tenderness were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Pain, Pyrexia
Clinical narrative: Body aches; Feverish, Temperature- 99.9; This is a spontaneous report received from a non-contactable consumer, the patient. A 52-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: P81301EP6955), via an unspecified route of administration on 24Mar2021 (at the age of 52-years-old), as a single dose for COVID-19 immunisation. Medical history included blood pressure (as reported). The patient did not have any allergies to medications, food, or other products. Concomitant medications included losartan (MANUFACTURER UNKNOWN) for unknown indication from unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to COVID-19 vaccine. On 25Mar2021, the patient experienced body aches and feverish with temperature of 99.9 (units unspecified). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome for the events general body pain and fever was recovering.  No follow-up attempts are possible. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Shoulder injury related to vaccine administration
Clinical narrative: SIRVA; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the right arm on 25Feb2021 at 08:30 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not have any allergies to medications, food, or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any concomitant medications with two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration on 04Feb2021 (at the age of 56-years-old), as a single dose for COVID-19 immunisation. On 25Feb2021 at 12:00, the patient experienced SIRVA (shoulder injury related to vaccine administration). The patient did not receive any treatment for the event SIRVA. The clinical outcome of the event SIRVA was not recovered at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Back pain, Hypertension, Palpitations
Clinical narrative: Heart palpation; back and shoulder pain; back and shoulder pain; High blood pressure; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the right arm on 25Mar2021 at 13:00 (at the age of 40-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient had a history of allergy to sofa. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 25Mar2021, the patient had experienced heart palpitation, shoulder and back pain and high blood pressure. Adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events heart palpitation, high blood pressure, back and shoulder pain was resolved on an unknown date in Mar2021. No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Headache, Pain, Pyrexia
Clinical narrative: Headache; Chills; Body aches; fever that last about 12 hours and got up to 101.6degrees.; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955), via an unspecified route of administration in left arm 23Mar2021 at 14:30 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not receive any medication within 2 weeks of vaccination. The patient had no allergies to food, medications, or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3248), via an unspecified route of administration in left arm 03Mar2021 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Mar2021 at 11:30, the patient experienced headache, chills and body aches. Then it quickly progressed to a fever that last about 12 hours and got up to 101.6 degrees. On 25Mar2021, woke up at 5 am with the fever, chills and body aches gone, but a headache was still lingering. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for adverse event. The clinical outcome of the events chills, body aches and fever were recovered on 25Mar2021 and headache was recovering at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Buttock injury, Herpes zoster, Hyperhidrosis, Rash
Clinical narrative: Not sure if this is related to the vaccine but 6 days later I woke up drenched in sweat.; Rash like area; with raised bump on buttocks; It seems to be a shingles outbreak; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613) via an unspecified route of administration in the left arm on 18Mar2021 at 15:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not have allergies to medications, food, or other products. Concomitant medications were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient had not received any other vaccines within 4 weeks prior to the COVID vaccine. On 24Mar2021 (6 days after vaccination), the patient woke up drenched in sweat and had a rash like area with raised bump on buttocks, that seemed to be a shingles outbreak. The patient was not sure if that was related to the vaccination. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcomes of the events drenched in sweat and had a rash like area with raised bump on buttocks, that seemed to be a shingles outbreak were unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Chills, Fatigue, Headache, Pyrexia
Clinical narrative: Slight fever of 100; Chills; slight headache; Tiredness; Body weakness; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non pregnant female patient received her second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EL3248), in right arm on 24Mar2021 at 13:15 (at the age of 44-year-old), as single dose for COVID-19 immunisation. The patient previously received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EL3248), in right arm on 03Mar2021 at 15:30 (at the age of 44-year-old), as single dose for COVID-19 immunisation. Medical history of the patient was reported as not applicable. Patient had no known allergies to medications, food or other products. The patient did not receive any other medication within 2 weeks of vaccination. The patient had not received any other vaccines within 4 weeks prior to the COVID vaccine. It was unsure whether, prior to vaccination the patient was not diagnosed with COVID-19. Since vaccination, the patient had not tested for COVID-19. On 24Mar2021 at 21:00, the patient experienced slight fever (100), chills, slight headache and body weakness/tiredness. No therapeutic measures were taken for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events slight fever, chills, slight headache and body weakness/tiredness were recovering at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Pain, Pyrexia, Swelling face
Clinical narrative: Worst headache; bad bodyaches; fever; puffy face; This is a spontaneous report from a non-contactable consumer, the patient. A 47-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613), via an unspecified route of administration in the right arm on 23Mar2021 at 18:15 (at the age of 47-years-old), as a single dose for COVID-19 immunisation. Medical history included COVID-19, which was diagnosed prior to the vaccination. The patient did not have any allergies to medications, food, or other products. Concomitant medication included thyroid (ARMOUR THYROID) for unknown indication and from an unknown date. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Since the vaccination, patient had not been tested for COVID-19. On 24Mar2021, the patient experienced worst headache, bad body aches, fever and puffy face. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event worst headache, bad body aches, fever and puffy face were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia, Fatigue, Headache
Clinical narrative: Metallic taste in my mouth; Tired; Headache; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204), via an unspecified route of administration in the right arm on 04Mar2021 at 11:15 (at the age 59-years-old) and a second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955), via an unspecified route of administration in the right arm on 25Mar2021 at 11:30 (at the age 59-year-old), each as a single dose for COVID-19 immunisation. The patient's medical history and concomitant medication were not reported. The patient previously received morphine (MANUFACTURER UNKNOWN) for an unspecified indication and experienced allergy. The patient did not receive any other vaccine within four weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date in Mar2021, the patient experienced metallic taste in mouth, tired and headache. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome of metallic taste in mouth, tired and headache were not resolved.  No follow-up attempts are needed. No further information is expected.